Anebulo Pharmaceuticals Inc. Announces Plans to Go Private

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company based in Lakeway, United States, has recently announced plans to go private, leading to a significant surge in its stock price. The company, which specializes in developing treatments for substance use disorders, including cannabinoid overdose, has been trading on the Nasdaq stock exchange.

Stock Surge Following Announcement

On July 23, 2025, Anebulo Pharmaceuticals’ stock experienced a notable increase following the approval of its plan to go private. This development was reported by multiple financial news sources, including Investing.com and its regional counterparts in India and Canada. The company’s stock, which closed at $1.83 on July 21, 2025, saw a sharp rise as investors reacted to the news.

Reverse Stock Split Strategy

In addition to the plan to go private, Anebulo Pharmaceuticals has outlined a strategy involving a reverse stock split. This move is part of the company’s broader effort to restructure its financial standing and potentially attract private investors. The reverse stock split is intended to consolidate the number of shares outstanding, thereby increasing the stock price and making the company more appealing to private equity firms or other potential buyers.

Company Overview

Anebulo Pharmaceuticals, Inc. operates within the Health Care sector and is listed on the Nasdaq. The company has a market capitalization of $67,380,000 USD. Despite a negative price-to-earnings ratio of -6.13, reflecting its current financial challenges, Anebulo remains focused on its mission to develop innovative treatments for addiction. The company’s 52-week high was $3.08 on September 19, 2024, while its 52-week low was $0.80 on December 19, 2024.

Conclusion

The decision to go private marks a significant shift for Anebulo Pharmaceuticals, Inc., as it seeks to navigate its financial landscape and continue its work in the field of substance use disorder treatments. The stock market’s positive reaction underscores investor confidence in the company’s strategic direction and potential for future growth.